ReviewViruses2019
Yellow Fever: Integrating Current Knowledge with Technological Innovations to Identify Strategies for Controlling a Re-Emerging Virus.
Review in Viruses, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 38 citations in OpenAlex.
- A Review of Yellow Fever: Epidemiology, Pathogenesis, Clinical Manifestations, Treatment, Prevention, and Prognosis.Cureus · 2026Review
- NS5-targeting nucleoside analogs inhibit dengue virus and other flaviviruses.PLoS pathogens · 2026Article
- Review
- Therapeutic, preventive, and pathogenetic advances in viral hepatitis.Frontiers in cellular and infection microbiology · 2026Review
- Ring vaccination and vector control as control strategies for potential yellow fever outbreak in an Asian city.Infectious Disease Modelling · 2025Article
- Yellow Fever in Non-Human Primates: A Veterinary Guide from a One Health Perspective.Veterinary sciences · 2025Review
- An Imported Yellow Fever Adverse Events Following Immunization Case Identified by Targeted Next-Generation Sequencing - Guangdong Province, China, October 2024.China CDC weekly · 2025Article
- Article
- Inactivation of yellow fever virus by WHO-recommended hand rub formulations and surface disinfectants.PLoS neglected tropical diseases · 2024Article
- Review
- Mechanism of Immune Evasion in Mosquito-Borne Diseases.Pathogens (Basel, Switzerland) · 2023Review
- Neuropathology of yellow fever autopsy cases.Tropical diseases, travel medicine and vaccines · 2023Article
- Rifapentine is an entry and replication inhibitor against yellow fever virus both in vitro and in vivo.Emerging microbes & infections · 2022Article
- Phenotypic and Genetic Studies of the Viral Lineage Associated with the Recent Yellow Fever Outbreak in Brazil.Viruses · 2022Article
- AT-752, a double prodrug of a guanosine nucleotide analog, inhibits yellow fever virus in a hamster model.PLoS neglected tropical diseases · 2022Article
- A yellow fever virus NS4B inhibitor not only suppresses viral replication, but also enhances the virus activation of RIG-I-like receptor-mediated innate immune response.PLoS pathogens · 2022Article
- Isolation and Genomic Characterization of Echovirus 11 from faeces of a Non-Human Primate in Nigeria.EcoHealth · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Yellow fever virus (YFV) represents a re-emerging zoonotic pathogen, transmitted by mosquito vectors to humans from primate reservoirs. Sporadic outbreaks of YFV occur in endemic tropical regions, causing a viral hemorrhagic fever (VHF) associated with high mortality rates. Despite a highly effective vaccine, no antiviral treatments currently exist. Therefore, YFV represents a neglected tropical disease and is chronically understudied, with many aspects of YFV biology incompletely defined including host range, host-virus interactions and correlates of host immunity and pathogenicity. In this article, we review the current state of YFV research, focusing on the viral lifecycle, host responses to infection, species tropism and the success and associated limitations of the YFV-17D vaccine. In addition, we highlight the current lack of available treatments and use publicly available sequence and structural data to assess global patterns of YFV sequence diversity and identify potential drug targets. Finally, we discuss how technological advances, including real-time epidemiological monitoring of outbreaks using next-generation sequencing and CRISPR/Cas9 modification of vector species, could be utilized in future battles against this re-emerging pathogen which continues to cause devastating disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.